New Approaches to Shifting the Migraine Treatment Paradigm
The standard of care paradigm for migraine treatment has been based almost exclusively on approaches that grew out of the happenstance use of market pharmaceuticals. Only methysergide, which has long since been removed from use for safety concerns, the ergotamine family of drugs, and the triptans we...
Main Authors: | Brian Johnson, Frederick G. Freitag |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pain Research |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpain.2022.873179/full |
Similar Items
-
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
by: Damiana Scuteri, et al.
Published: (2021-09-01) -
CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine
by: Francesca Finelli, et al.
Published: (2024-01-01) -
Progress in treating migraines: promising prospects for a better tomorrow
by: Seyed-Amirabbas Ahadiat, et al.
Published: (2023-08-01) -
New Generation Gepants: Migraine Acute and Preventive Medications
by: David Moreno-Ajona, et al.
Published: (2022-03-01) -
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
by: Matilde Capi, et al.
Published: (2021-04-01)